OncoCyte Corp OCX.OQ OCX.O is expected to show a fall in quarterly revenue when it reports results on March 24 for the period ending December 31 2024
The Irvine California-based company is expected to report a 68.2% decrease in revenue to $100 thousand from $314 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for OncoCyte Corp is for a loss of 43 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for OncoCyte Corp is $4.13, above its last closing price of $3.40.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.44 | -0.44 | -0.98 | Missed | -124.8 |
Jun. 30 2024 | -0.55 | -0.56 | -0.36 | Beat | 35.6 |
Mar. 31 2024 | -0.65 | -0.67 | -1.13 | Missed | -69.1 |
Dec. 31 2023 | -1.14 | -2.12 | Missed | -86.5 | |
Sep. 30 2023 | -1.00 | -1.01 | -0.81 | Beat | 19.6 |
Jun. 30 2023 | -0.68 | -1.30 | -1.07 | Beat | 17.7 |
Mar. 31 2023 | -1.31 | -1.84 | 0.40 | Beat | 121.7 |
Dec. 31 2022 | -1.88 | -8.00 | Missed | -324.6 |
This summary was machine generated March 21 at 23:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。